[実世界のデータ,シリコモデリング,ネットワーク薬理を用いた統合的な薬剤発見戦略]

Hirofumi Hamano¹, Yuta Tanaka², Yoshito Zamami¹

¹Department of Pharmacy, Medical Development Field, Okayama University.

Nihon yakurigaku zasshi. Folia pharmacologica Japonica

|August 31, 2025

まとめ

この研究は,新しい治療法を発見するために,実世界のデータ,シリコスクリーニング,およびネットワーク薬理学を統合しています. 薬剤の再定位候補と様々な疾患に対する安全性を緩和する治療法を特定します.

科学分野:

計算生物学
薬理学について
バイオ情報学

背景:

免疫チェックポイント阻害剤は心筋炎を引き起こす可能性があります.
トラストズマブ耐性は,HER2陽性乳がんにおける課題です.
薬剤による外周神経症はいくつかの薬剤の重要な副作用です.

研究の目的:

実用データ,シリコスクリーニング,ネットワーク薬理を組み合わせた統合薬剤発見戦略を評価する.
特定の副作用や耐性がんに対する潜在的な治療介入とリスク軽減戦略を特定する.
薬剤発見における多層データベースのアプローチの有用性を実証する.

主な方法:

心筋炎を研究するために,トランスクリプトミックのデータと有害事象報告の分析.
薬物のシリコンスクリーニングのための化学情報学,機械学習,ドッキングシミュレーション
薬物誘発の周辺神経症を調査するための遺伝子モジュールのネットワークベースの分析.

主要な成果:

アラキドン酸代謝を標的とする非ステロイド性抗炎症薬は,心筋炎を予防することができる.
トラストズマブ耐性乳がんでは新しいYES1キナーゼ阻害剤が特定されました.
特定のスタチンは,共通の標的と神経変性経路を通じて,薬物誘発の周辺神経病変から保護することがあります.

結論:

多様なデータ (トランスクリプトミクス,化学構造,ネットワーク,現実世界のデータ) を統合することで,薬物の発見が容易になります.
このデータに基づいた戦略は薬剤の位置転換候補とリスクを軽減する治療法を特定できます
多層アプローチは,有効性と安全性に焦点を当てたトランスレーション薬剤発見の枠組みの開発に有望です.

さらに関連する動画

07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K

08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.1K

関連する概念動画

01:26

Drug Discovery: Overview

8.7K

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

8.7K

01:28

Structure-Activity Relationships and Drug Design

1.0K

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

1.0K

01:12

Analysis of Population Pharmacokinetic Data

382

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...

382

01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

223

Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...

223

01:20

Pharmacokinetic Models: Overview

1.1K

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...

1.1K

01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

126

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...

126

関連する実験動画